HomeCompareAMGN vs OLN

AMGN vs OLN: Dividend Comparison 2026

AMGN yields 2.77% · OLN yields 2.77%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMGN wins by $140.3K in total portfolio value
10 years
AMGN
AMGN
● Live price
2.77%
Share price
$349.00
Annual div
$9.66
5Y div CAGR
48.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$164.2K
Annual income
$69,743.86
Full AMGN calculator →
OLN
OLN
● Live price
2.77%
Share price
$28.88
Annual div
$0.80
5Y div CAGR
-0.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.8K
Annual income
$327.63
Full OLN calculator →

Portfolio growth — AMGN vs OLN

📍 AMGN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMGNOLN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMGN + OLN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMGN pays
OLN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMGN
Annual income on $10K today (after 15% tax)
$235.27/yr
After 10yr DRIP, annual income (after tax)
$59,282.28/yr
OLN
Annual income on $10K today (after 15% tax)
$235.46/yr
After 10yr DRIP, annual income (after tax)
$278.49/yr
At 15% tax rate, AMGN beats the other by $59,003.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMGN + OLN for your $10,000?

AMGN: 50%OLN: 50%
100% OLN50/50100% AMGN
Portfolio after 10yr
$94.0K
Annual income
$35,035.74/yr
Blended yield
37.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AMGN right now

AMGN
Analyst Ratings
22
Buy
13
Hold
3
Sell
Consensus: Buy
Price Target
$347.73
-0.4% upside vs current
Range: $185.00 — $432.00
Altman Z
2.3
Piotroski
8/9
OLN
Analyst Ratings
11
Buy
22
Hold
2
Sell
Consensus: Hold
Price Target
$22.40
-22.4% upside vs current
Range: $18.00 — $26.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMGN buys
0
OLN buys
0
No recent congressional trades found for AMGN or OLN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMGNOLN
Forward yield2.77%2.77%
Annual dividend / share$9.66$0.80
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR48.6%-0.1%
Portfolio after 10y$164.2K$23.8K
Annual income after 10y$69,743.86$327.63
Total dividends collected$133.8K$3.0K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyHold
Analyst price target$347.73$22.40

Year-by-year: AMGN vs OLN ($10,000, DRIP)

YearAMGN PortfolioAMGN Income/yrOLN PortfolioOLN Income/yrGap
1← crossover$11,111$411.31$10,977$276.73+$134.00AMGN
2$12,524$634.70$12,029$283.60+$495.00AMGN
3$14,394$993.52$13,161$290.16+$1.2KAMGN
4$16,987$1,585.83$14,379$296.41+$2.6KAMGN
5$20,776$2,599.19$15,687$302.34+$5.1KAMGN
6$26,645$4,414.70$17,093$307.98+$9.6KAMGN
7$36,373$7,863.06$18,603$313.31+$17.8KAMGN
8$53,826$14,907.12$20,224$318.36+$33.6KAMGN
9$88,231$30,636.84$21,963$323.13+$66.3KAMGN
10$164,151$69,743.86$23,828$327.63+$140.3KAMGN

AMGN vs OLN: Complete Analysis 2026

AMGNHealthcare

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Full AMGN Calculator →

OLNStock

Olin Corporation manufactures and distributes chemical products in the United States, Europe, and internationally. It operates through three segments: Chlor Alkali Products and Vinyls; Epoxy; and Winchester. The Chlor Alkali Products and Vinyls segment offers chlorine and caustic soda, ethylene dichloride and vinyl chloride monomers, methyl chloride, methylene chloride, chloroform, carbon tetrachloride, perchloroethylene, hydrochloric acid, hydrogen, bleach products, potassium hydroxide, chlorinated organics intermediates and solvents, and sodium hypochlorite. The Epoxy segment provides epoxy materials and precursors, including aromatics, such as acetone, bisphenol, cumene, and phenol, as well as allyl chloride, epichlorohydrin, and glycerin used for the manufacturers of polymers, resins and other plastic materials, and water purification; liquid and solid epoxy resins that are used in adhesives, marines, protective coatings, composites, and flooring; and converted epoxy resins and additives for use in electrical laminates, paints and coatings, wind blades, electronics, and construction. The Winchester segment offers sporting ammunition products, including shotshells, small caliber centerfire, and rimfire ammunition products for hunters and recreational shooters, and law enforcement agencies; small caliber military ammunition products for use in infantry and mounted weapons; and industrial products comprising gauge loads and powder-actuated tool loads for maintenance applications in power and concrete industries, and powder-actuated tools in construction industry. The company markets its products through its sales force, as well as directly to various industrial customers, mass merchants, retailers, wholesalers, other distributors, and the U.S. Government and its prime contractors. Olin Corporation was incorporated in 1892 and is based in Clayton, Missouri.

Full OLN Calculator →
📬

Get this AMGN vs OLN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMGN vs SCHDAMGN vs JEPIAMGN vs OAMGN vs KOAMGN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.